Secukinumab shows positive effects in HS at 52 weeks
Patients with moderate to severe hidradenitis suppurativa (HS) treated with secukinumab demonstrate sustained efficacy and symptom...
Secukinumab shows positive effects in HS at 52 weeks
Dupilumab effective in relieving AD symptoms in children aged six months to six years
New monoclonal antibody shows efficacy in CLE
Misuse of alcohol affects response to psoriasis treatment
Two-year data indicates bimekizumab maintains high levels of psoriatic skin clearance
Herpes zoster more common in patients with psoriasis, with a higher incidence in those on biologics
Biologics for psoriasis patients may delay or stop progress to psoriatic arthritis
HORIZON program provides treatment recommendations for patients with moderate to severe psoriasis